Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Viridian Therapeutics Inc (VRDN)

Viridian Therapeutics Inc (VRDN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 817,867
  • Shares Outstanding, K 62,768
  • Annual Sales, $ 310 K
  • Annual Income, $ -237,730 K
  • 60-Month Beta 1.07
  • Price/Sales 2,848.55
  • Price/Cash Flow N/A
  • Price/Book 3.19
Trade VRDN with:

Options Overview Details

View History
  • Implied Volatility 98.72% ( +2.42%)
  • Historical Volatility 42.59%
  • IV Percentile 92%
  • IV Rank 73.71%
  • IV High 120.65% on 09/27/23
  • IV Low 37.21% on 08/04/23
  • Put/Call Vol Ratio 0.50
  • Today's Volume 33
  • Volume Avg (30-Day) 423
  • Put/Call OI Ratio 3.21
  • Today's Open Interest 12,037
  • Open Int (30-Day) 8,965

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -1.07
  • Number of Estimates 7
  • High Estimate -0.88
  • Low Estimate -1.36
  • Prior Year -1.61
  • Growth Rate Est. (year over year) +33.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.20 +4.10%
on 04/25/24
18.02 -29.52%
on 03/27/24
-4.85 (-27.64%)
since 03/25/24
3-Month
12.20 +4.10%
on 04/25/24
21.46 -40.82%
on 02/28/24
-6.98 (-35.47%)
since 01/25/24
52-Week
10.93 +16.25%
on 10/25/23
28.99 -56.19%
on 05/02/23
-15.52 (-55.00%)
since 04/25/23

Most Recent Stories

More News
2 Growth Stocks Wall Street Analysts Think Can Double in Value

Is now a good time to buy these promising healthcare stocks?

VRDN : 12.70 (-2.53%)
DNA : 0.7777 (-8.05%)
Why Shares of Viridian Therapeutics Are Falling Tuesday

The company announced preliminary trial results for its lead therapy.

HZNP : 116.30 (+0.04%)
VRDN : 12.70 (-2.53%)
Why These 2 Nasdaq Biotech Stocks Fell Hard Tuesday Morning

Broader markets seemed likely to start out on a positive note despite these two outliers.

COMP : 3.22 (-3.30%)
$NASX : 15,611.76 (-0.64%)
VRDN : 12.70 (-2.53%)
IOVA : 11.54 (-1.45%)
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates

Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -61% and 67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

VRDN : 12.70 (-2.53%)
SPRO : 1.4300 (+0.70%)
Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Lags Revenue Estimates

Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -56.94% and 85.25%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...

VRDN : 12.70 (-2.53%)
ETON : 3.12 (-2.80%)
Cara Therapeutics (CARA) Reports Q4 Loss, Misses Revenue Estimates

Cara (CARA) delivered earnings and revenue surprises of -69.70% and 76.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

CARA : 0.7000 (+4.23%)
VRDN : 12.70 (-2.53%)
Syros Pharmaceuticals, Inc. (SYRS) Reports Q4 Loss, Lags Revenue Estimates

Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -0.79% and 123.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...

SYRS : 5.10 (+0.59%)
VRDN : 12.70 (-2.53%)
Wall Street Analysts Predict an 89% Upside in Viridian Therapeutics, Inc. (VRDN): Here's What You Should Know

The mean of analysts' price targets for Viridian Therapeutics, Inc. (VRDN) points to an 89.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

VRDN : 12.70 (-2.53%)
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates

Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of 1.15% and 131.59%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

VRDN : 12.70 (-2.53%)
LVTX : 2.64 (-3.65%)
Rani Therapeutics Holdings, Inc. (RANI) Reports Q3 Loss, Lags Revenue Estimates

Rani Therapeutics Holdings, Inc. (RANI) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

RANI : 6.56 (-6.15%)
VRDN : 12.70 (-2.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Viridian Therapeutics Inc. is a biotechnology company advancing new treatments for patients suffering from serious diseases. The company's program includes VRDN-001, which is in clinical stage. Viridian Therapeutics Inc., formerly known as miRagen Therapeutics Inc., is based in BOULDER, Colo.

See More

Key Turning Points

3rd Resistance Point 13.79
2nd Resistance Point 13.37
1st Resistance Point 13.04
Last Price 12.70
1st Support Level 12.28
2nd Support Level 11.86
3rd Support Level 11.53

See More

52-Week High 28.99
Fibonacci 61.8% 22.09
Fibonacci 50% 19.96
Fibonacci 38.2% 17.83
Last Price 12.70
52-Week Low 10.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar